Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of a revised Notice of Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH), relating to the approximately $2.0 million funding award for DARE-PTB1, Daré's investigational intravaginal ring (IVR) for the prevention of preterm birth. The notice, issued March 11, 2026, extends the budget and project period for the second tranche of the award, or approximately $1.0 million, through November 30, 2026. The total NIH funding obligated under the program is approximately $2.0 million.

DARE-PTB1 is a novel, investigational IVR designed to deliver bio-identical progesterone continuously for up to a 14-day period. It is being developed to reduce the risk of preterm birth in at-risk women, a condition for which there are currently no FDA-approved treatments.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.